EVERPRIDE BIOPHARMACEUTICAL COMPANY LTD : <u>MAKING MONEY FROM WORMS</u>

Everpride Biopharmaceutical Company Ltd has just one product, known as '*Plasmin Capsule*', a Chinese '*medicine*', which is said to be derived from earthworms.

This 'medicine', claims the Placing Prospectus of this Company, 'may be used for medical treatment for cerebral embolism, cerebral infarction, myocardial infarction, hypertension, complications of diabetes, and thromboangitis, as well as the prevention of formation of blood clots.' (Page 54 of the Prospectus)

Gadzooks! This is exactly the medicine, for which the American Medical Association has been waiting: It could mean the end to heart attacks, the largest killer in the US, and strokes!

In case subscribers have not guessed it, Everpride is the latest listing on The Growth Enterprise Market of The Stock Exchange of Hongkong Ltd.

It is to be known, starting today, by Stock Code Number 8019.

The history of this Company goes back to the day that Mr Chung Chi Mang, the 39-year-old Founder and Chairman of Everpride, funded a research project at a cost of 200,000 renminbi (about \$HK188,413).

That was back in 1992.

That research project was headed by a Mr Shan Hong Ren, a gentlemen (obviously not a doctor) said to have been a former professor at Shanxi College of Medicine and a Director of Biochemistry Institute of the People's Republic of China (PRC). (Page 54)

Today, Plasmin Capsule is a 'State Class 2 Protected Product of Chinese Medicine' and, as such, it is entitled to an administrative protection period of 7 years, commencing September 28, 1999. (Page One)

Everpride wants to cash in on this discovery and, so, it is making its pitch to investors of the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC) in order to Place 140 million new, 10-cent shares at a Premium of 39.50 cents per share.

Chairman Chung Chi Mang is, also, taking this opportunity to Place 10 million of his personal shares in the Company, on the same basis as the Company's ... <u>CLICK TO ORDER FULL ARTICLE</u>

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

If readers feel that they would like to voice their opinions about that which

they have read in TARGET, please feel free to e-mail your views to <u>editor@targetnewspapers.com</u> or <u>targnews@hkstar.com</u>. TARGET does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.

Site Meter